Shionogi & Co., Ltd. (OTCMKTS:SGIOF – Get Free Report) and Clene (NASDAQ:CLNN – Get Free Report) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, analyst recommendations, valuation, institutional ownership and profitability.
Analyst Recommendations
This is a breakdown of recent recommendations and price targets for Shionogi & Co., Ltd. and Clene, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Shionogi & Co., Ltd. | 0 | 0 | 0 | 0 | 0.00 |
| Clene | 1 | 0 | 6 | 0 | 2.71 |
Clene has a consensus target price of $33.25, indicating a potential upside of 563.67%. Given Clene’s stronger consensus rating and higher probable upside, analysts plainly believe Clene is more favorable than Shionogi & Co., Ltd..
Institutional and Insider Ownership
Earnings and Valuation
This table compares Shionogi & Co., Ltd. and Clene”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Shionogi & Co., Ltd. | N/A | N/A | N/A | $90.94 | 0.19 |
| Clene | $200,000.00 | 320.14 | -$26.17 million | ($3.20) | -1.57 |
Shionogi & Co., Ltd. has higher earnings, but lower revenue than Clene. Clene is trading at a lower price-to-earnings ratio than Shionogi & Co., Ltd., indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Shionogi & Co., Ltd. and Clene’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Shionogi & Co., Ltd. | N/A | N/A | N/A |
| Clene | -25,009.70% | N/A | -137.98% |
Summary
Clene beats Shionogi & Co., Ltd. on 6 of the 10 factors compared between the two stocks.
About Shionogi & Co., Ltd.
Shionogi & Co., Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan. It offers Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment; Cabenuva and Apretude an anti-HIV and HIV prophylactic drug; Xocova an oral COVID-19 treatment drug; Finibax a carbapenem antibiotic; Xofluza, an influenza antiviral drug; and Tivicay, an anti-HIV drug. It also develops S-872600 an influenza nasal vaccine; S-875670 anCOVID-19 nasal vaccine; S-540956 a nucleic acid adjuvant; S-554110 a nontuberculous mycobacterial infection; S-337395 for RSV infections; S-892216 for COVID-19 therapeutics; Olorofim for invasive aspergillosis; cefiderocol for aerobic gram-negative bacterial infections and infectious diseases; S-268019 a COVID-19 prophylactic vaccine; S-268019 a prophylactic vaccine for COVID-19; ensitrelvir for COVID-19 treatment and prevention; baloxavir for influenza virus infection; S-365598 for HIV infection; and S-555739 for suppressing aggravation of COVID-19. In addition, the company develops S-540956 for nucleic acid adjuvant; S-109802 for post-stroke spasticity; S-151128 for chronic pain; S-588210 and S-531011 for solid tumor; S-309309 for obesity; BPN14770 for Alzheimer's disease and fragile X syndrome; S-588410 for bladder cancer; S-488210 for head and neck squamous cell carcinoma; S-005151 for Acute ischemic stroke and epidermolysis bullosa; Rizmoic for opioid-induced constipation; ADR-001 for decompensated liver cirrhosis; S-222611 for malignant tumor; S-812217 for depression; GRT7039 for pain associated with osteoarthritis of the knee; SDT-001 for inattentive ADHD; S-588410 for esophageal cancer; SR-0379 for cutaneous ulcer; and S-723595 for type 2 diabetes. The company was formerly known as Shionogi Shoten Co., Ltd. and changed its name to Shionogi & Co., Ltd. in 1943. Shionogi & Co., Ltd. was founded in 1878 and is headquartered in Osaka, Japan.
About Clene
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company also develops CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease and to provide immune support for symptom resolution. In addition, it markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.
Receive News & Ratings for Shionogi & Co. Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shionogi & Co. Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.
